Free Trial

DURECT (DRRX) Competitors

DURECT logo
$0.57 -0.02 (-3.44%)
As of 07/25/2025 04:00 PM Eastern

DRRX vs. APLT, RPTX, CRVO, ASRT, STRO, HOWL, SCLX, IKNA, BRNS, and MNOV

Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Applied Therapeutics (APLT), Repare Therapeutics (RPTX), CervoMed (CRVO), Assertio (ASRT), Sutro Biopharma (STRO), Werewolf Therapeutics (HOWL), Scilex (SCLX), Ikena Oncology (IKNA), Barinthus Biotherapeutics (BRNS), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry.

DURECT vs. Its Competitors

Applied Therapeutics (NASDAQ:APLT) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Applied Therapeutics presently has a consensus price target of $6.10, indicating a potential upside of 1,170.83%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Applied Therapeutics is more favorable than DURECT.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
DURECT
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Applied Therapeutics had 2 more articles in the media than DURECT. MarketBeat recorded 3 mentions for Applied Therapeutics and 1 mentions for DURECT. DURECT's average media sentiment score of 1.87 beat Applied Therapeutics' score of 0.88 indicating that DURECT is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Therapeutics Positive
DURECT Very Positive

Applied Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Applied Therapeutics has a net margin of 0.00% compared to DURECT's net margin of -91.54%. Applied Therapeutics' return on equity of -184.67% beat DURECT's return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -184.67% -84.02%
DURECT -91.54%-267.36%-64.00%

DURECT has higher revenue and earnings than Applied Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$460K147.74-$105.62M-$0.43-1.12
DURECT$2.03M8.68-$8.32M-$0.15-3.78

Summary

Applied Therapeutics beats DURECT on 10 of the 16 factors compared between the two stocks.

Get DURECT News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRRX vs. The Competition

MetricDURECTMED IndustryMedical SectorNASDAQ Exchange
Market Cap$18.24M$2.49B$5.69B$9.50B
Dividend YieldN/A1.65%4.58%4.01%
P/E Ratio-3.789.0528.1020.05
Price / Sales8.68612.51432.4890.19
Price / CashN/A165.2136.2258.56
Price / Book1.965.168.665.87
Net Income-$8.32M$30.99M$3.25B$258.55M
7 Day Performance6.00%7.74%4.22%3.73%
1 Month Performance-8.69%16.27%10.51%11.75%
1 Year Performance-66.02%-1.88%34.40%18.03%

DURECT Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRRX
DURECT
1.1933 of 5 stars
$0.57
-3.4%
N/A-65.6%$18.24M$2.03M-3.7880Positive News
Gap Down
APLT
Applied Therapeutics
4.4001 of 5 stars
$0.46
-0.4%
$6.10
+1,226.1%
-90.8%$65.39M$460K-1.0730News Coverage
Analyst Upgrade
RPTX
Repare Therapeutics
2.8661 of 5 stars
$1.50
-0.7%
$4.50
+200.0%
-60.0%$64.77M$53.48M-0.50180
CRVO
CervoMed
3.2514 of 5 stars
$8.43
+13.8%
$22.57
+167.8%
-37.5%$64.49M$9.74M-3.874News Coverage
Analyst Forecast
ASRT
Assertio
2.3167 of 5 stars
$0.70
+3.3%
$2.75
+295.7%
-49.7%$64.46M$124.96M-2.1720Positive News
STRO
Sutro Biopharma
4.162 of 5 stars
$0.80
+5.3%
$6.11
+664.3%
-79.3%$64.19M$62.04M-0.27240News Coverage
HOWL
Werewolf Therapeutics
4.0485 of 5 stars
$1.40
-0.7%
$8.33
+495.2%
-50.4%$63.27M$1.88M-0.8440
SCLX
Scilex
2.3844 of 5 stars
$8.60
-2.9%
$455.00
+5,190.7%
-79.9%$61.59M$56.59M-0.3080News Coverage
IKNA
Ikena Oncology
2.8301 of 5 stars
$1.27
flat
$3.00
+136.2%
-14.9%$61.29M$9.16M-1.4870News Coverage
Earnings Report
Analyst Forecast
Stock Split
High Trading Volume
BRNS
Barinthus Biotherapeutics
3.6737 of 5 stars
$1.97
+31.5%
$6.25
+217.3%
+22.6%$60.41M$14.97M-1.20107Positive News
Gap Up
High Trading Volume
MNOV
MediciNova
1.6029 of 5 stars
$1.26
+2.4%
$7.00
+455.6%
+12.3%$60.33M$1M-5.4810News Coverage
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:DRRX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners